Yale researchers develop first FDA-approved drug to delay autoimmune diseases
Kevan Herold of Yale School of Medicine led clinical trials of teplizumab, a drug that delays the development of type 1 diabetes, which affects about 1.95 million Americans. Chloe Nield and James Steele 11:59 p.m., November 30, 2022 Staff Journalist and Contributing Journalist Eric Wang, Senior Photographer Teplizumab, a drug that delays type 1 diabetes, …
Yale researchers develop first FDA-approved drug to delay autoimmune diseases Read More »
